First Department of Internal Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.
Division of Clinical Nutrition and Metabolism, Wakayama Medical University, Wakayama 641-8509, Japan.
Endocr J. 2020 Aug 28;67(8):859-868. doi: 10.1507/endocrj.EJ19-0604. Epub 2020 May 25.
Thyroid dysfunction and thyroid autoimmunity (TAI) have been reported to be linked to infertility, pregnancy loss and preterm birth. Infertile women undergoing assisted reproductive technology are recommended to maintain thyroid stimulating hormone (TSH) levels below 2.5 μIU/mL. It is unclear, however, whether levothyroxine (L-T4) treatment decreases the effects of TAI on fertility and pregnancy outcome in infertile women. We therefore aimed to clarify the influence of TAI on pregnancy undergoing L-T4 treatment for hypothyroidism. Prospectively recruited to this study were the 595 infertile women who visited the Utsunomiya Ladies Clinic between January 2013 and December 2015. Five patients with Graves' disease were excluded. Clinical profiles of 590 women were as follows: proportion of SCH = 19.6%, thyroid peroxidase antibody (TPOAb) positivity = 10.4%, and thyroglobulin antibody (TgAb) positivity = 15.1%. Fertility was not affected by any thyroid-associated factors. Regarding pregnancy outcomes, TPOAb titers were significantly higher in women who had miscarriage than in those progressed to delivery (46.4 ± 114.1 vs. 18.9 ± 54.6 IU/mL, p = 0.039), notably in those undergoing intrauterine insemination (p = 0.046) and in vitro fertilization (p = 0.023). Multivariate logistic regression analysis revealed that higher age (odds ratio 26.4, p < 0.001) and higher TPOAb titer (odds ratio 11.8, p = 0.043) were risk factors for miscarriage. Higher TPOAb titer should be considered as one of the risk factors for miscarriage in infertile women, even if they have been treated with L-T4 for hypothyroidism.
甲状腺功能障碍和自身免疫性甲状腺疾病(TAI)与不孕、流产和早产有关。接受辅助生殖技术的不孕妇女建议将促甲状腺激素(TSH)水平保持在 2.5μIU/mL 以下。然而,尚不清楚左旋甲状腺素(L-T4)治疗是否会降低 TAI 对不孕妇女生育和妊娠结局的影响。因此,我们旨在阐明 TAI 对接受 L-T4 治疗甲状腺功能减退症的妊娠的影响。本研究前瞻性纳入了 2013 年 1 月至 2015 年 12 月期间在宇都宫女士诊所就诊的 595 名不孕妇女。排除了 5 名格雷夫斯病患者。590 名妇女的临床特征如下:SCH 比例为 19.6%,甲状腺过氧化物酶抗体(TPOAb)阳性率为 10.4%,甲状腺球蛋白抗体(TgAb)阳性率为 15.1%。生育能力不受任何甲状腺相关因素的影响。关于妊娠结局,流产组妇女的 TPOAb 滴度明显高于分娩组(46.4±114.1 vs. 18.9±54.6IU/mL,p=0.039),尤其是在接受宫腔内人工授精(p=0.046)和体外受精(p=0.023)的患者中。多变量 logistic 回归分析显示,年龄较高(优势比 26.4,p<0.001)和 TPOAb 滴度较高(优势比 11.8,p=0.043)是流产的危险因素。即使不孕妇女接受 L-T4 治疗甲状腺功能减退症,较高的 TPOAb 滴度也应被视为流产的危险因素之一。